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Abstract
Background: The study aimed to explore the correlation between the expression of TREX1 and the metastasis and
the survival time of patients with osteosarcoma as well as biological characteristics of osteosarcoma cells for the
prognosis judgment of osteosarcoma.
Method: The correlation between the expression of TREX1 protein and the occurrence of pulmonary metastasis in
45 cases of osteosarcoma was analyzed. The CD133+ and CD133− cell subsets of osteosarcoma stem cells were sorted by
the flow cytometry. The tumorsphere culture, clone formation, growth curve, osteogenic and adipogenic differentiation,
tumor-formation ability in nude mice, sensitivity of chemotherapeutic drugs, and other cytobiology behaviors
were compared between the cell subsets in two groups; the expressions of stem cell-related genes Nanog and
Oct4 were compared; The expressions of TREX1 protein and mRNA were compared between the cell subsets in
two groups. The data was statistically analyzed. The measurement data between the two groups were compared using t
test. The count data between the two groups were compared using χ2 test and Kaplan–Meier survival analysis. A P value
<0.05 indicated that the difference was statistically significant.
Results: The expression of TREX1 protein in patients with osteosarcoma in the metastasis group was significantly lower
than that in the non-metastasis group. The difference was statistically significant (P < 0.05). Up to the last follow-up visit,
the former average survival time was significantly lower than that of the latter, and the difference was statistically
significant (P < 0.05). The expression of TREX1 in human osteosarcoma CD133+ cell subsets was significantly lower than
that in CD133- cell subsets. Stemness-related genes Nanog and Oct4 were highly expressed in human osteosarcoma
CD133+ cell subsets with lower expression of TREX1; the biological characteristics identification experiment showed
that human CD133+ cell subsets with low TREX1 expression could form tumorspheres, the number of colony forming
was more, the cell proliferation ability was strong, the osteogenic and adipogenic differentiation potential was big, the
tumor-forming ability in nude mice was strong, and the sensibility of chemotherapeutics drugs on cisplatin was low.
Conclusions: The expression of TREX1 may be related to metastasis in patients with osteosarcoma. The expression of
TREX1 was closely related to the cytobiology characteristics of osteosarcoma stem cell. TREX1 can play an important
role in the occurrence and development processes. And, TREX1 is expected to become an effective new index for the
evaluation of the prognosis.
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Background
Pulmonary metastasis occurs in about 20% of the pa-
tients with osteosarcoma during the time of first visit.
These are usually resistant to conventional chemother-
apy drugs [1, 2]. A large number of clinical trials have
proven that the biological characteristics of lung metastasis
were not consistent with the primary tumor, thus leading
to chemotherapy resistance [2–5]. Numerous evidence
supported that osteosarcoma stem cells were the reason
for pulmonary metastasis and chemotherapy drug resist-
ance [6, 7]. Therefore, further study on the biological char-
acteristics of osteosarcoma stem cells and its biochemical
index are recommended to determine its relationship with
pulmonary metastasis and chemotherapy drug resistance.
This might be a precedent in the development of a specific
targeted drug therapy; improving the prognosis and the
overall survival of patients with osteosarcoma.
TREX1 is main 3′–5′ exonuclease in mammalian
animals. It has obvious preference for the special DNA
sequence. The preference degree is related to the activity
of exonuclease [8]. The present study has suggested that
TREX1 gene may be related to the immunity of tumor
and lupus erythematosus [9–11] and the clinical outcome
of cancer [12]. TREX1 gene mutation or gene silencing
can mediate DNA damage and cell death [13, 14]. There-
fore, the low expression of TREX1 gene may reduce the
cytotoxicity of CTL and NK on tumor cells, so that the
tumor cells occur to immune escape and the tumor
growth can be promoted. However, it was unclear whether
the expression of TREX1 was related to the occurrence,
development, and metastasis of osteosarcoma. It is neces-
sary to clarify whether the osteosarcoma occurs to metas-
tasis for the existing treatments and estimate the
osteosarcoma condition using the specific indicator, in
order to provide the diagnostic indicator for improving
the clinical treatment.
The correlation between the expression of TREX1, clin-
ical manifestation, and prognosis of osteosarcoma in pa-
tients as well as biological characteristics of osteosarcoma
stem cell was investigated in the paper, the relationship
between the expression of TREX1 and osteosarcoma stem
cells was clarified, so as to explore the correlation between
the expression of TREX1 and the metastasis risk and clin-
ical prognosis of patients with osteosarcoma.
Methods
Patients, specimen, and data collection
Specimens from 45 cases of primary untreated osteosar-
coma between January 2004 and March 2011 were
included in this study. Inclusion criteria: after puncture
or incision biopsy specimens, all patients of osteosar-
coma were clearly pathological diagnosed by senior doc-
tor of pathology. The standard preoperative neoadjuvant
chemotherapy and postoperative chemotherapy for more
than two courses of treatment were operated for all pa-
tients; all patients’ operation treatments were performed
by the same senior doctors according to the patient
Enncking staging. Chemotherapy with adriamycin + cis-
platin + isofosfamide before operation, methotrexate + iso-
fosfamide was adopted when the effect of the
chemotherapy was poor. Postoperative chemotherapy was
carried out according to the preoperative chemotherapy.
Exclusion criteria: patients who did not conduct regular
neoadjuvant chemotherapy or surgical treatment in our
hospital for a variety of reasons.
In order to evaluate the development of local recur-
rence and distant metastases, following chemotherapy,
all patients were undergoing lung checkup by bone scan-
ning and lung CT scans every 3 months during the first
3 years after therapy and every 6 months thereafter.
The cohort included 23 males and 22 females, aged 8–
54 years-old (mean, 21 years old). The formalin-fixed and
paraffin-embedded surgical tumor samples were obtained
from the archives of the Department of Pathology, First
Affiliated Hospital, Fujian Medical University, Fuzhou,
Fujian, China, for immunohistochemical staining. After
reviewing medical records and contacting the patients or
their relatives by telephone, follow-up information was
available up to December 31, 2014. The use of tissue
blocks and patient records was approved by the Ethics
Committee of the First Affiliated Hospital, Fujian Medical
University. The relevant clinical data included gender, age,
tumor location, local recurrence status, distant metastasis
status, and overall survival was recorded.
Immunohistochemical method for the expression test of
TREX1 protein
Anti-TREX1 monoclonal antibody (1:100, Abcam, USA)
was used for the expression test of TREX1 protein
through immunohistochemical method. Known positive
tissue specimens were used as positive control, single
PBS was applied as the antibody for the negative control.
Independent double-blind identification was applied for
every slice by two pathologists, ten representative high-
power field of vision was randomly selected and each
field of vision counted about 200 cells. And then, the
positive and negative expressions of TREX1 protein were
decided through the percentage of stained cells.
Cell lines and culture
The human osteosarcoma cell lines MNNG/HOS, MG-
63 and U-2 OS, which were purchased from the Chinese
Academy of Sciences (Shanghai, China) cell bank and
were used within 10 passages. They were placed in
DMEM culture medium, included 10% fetal calf serum,
100U/mL penicillin and 100 μg/mL streptomycin, and
placed in 75-mL flasks with filtered valves. All of the
cells were incubated at 37 °C in 5% CO2, and the
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medium changed every other day. After confluence, cells
were subdivided into new flasks for other experiments.
Flow cytometry and cell sorting
Cells were detached using 0.02% Trypsinization-EDTA
in phosphate-buffered saline (PBS), washed by PBS, and
then incubated with fluorescent-labelled monoclonal
antibodies human CD133/1 PE conjugated (Miltenyi,
German) or respective isotype (mouse anti-human
CD133 PE conjugated) controls. After washing steps, the
labelled cells were sorted by flow cytometry (Becton and
Dickinson, USA), collecting cells with CD133+ and
CD133− respective, for spheres, growth analysis, mono-
clonal formation, and the sensitivity of chemotherapy.
Tumorspheres
Cells were seeded in a 6-well plates for a density of
1.0 × 106cells/well and cultivated as spheres in DMEM-
F12(Life Technologies medium with B-27 (2%; Invitrogen),
L-gln(1×; Invitrogen), Life (20 ng/mL; Invitrogen), human
EGF (20 ng/mL; Invitrogen) and human bFGF (20 ng/mL;
Invitrogen). We use fresh medium every other day, and
after culturing for 2~3 days, spheres were visible at
inverted phase-contrast microscope (Olympus, Japan).
Cell proliferation
Cell were plated in 96-well plates at a concentration of
3.0 × 103 cells/well. After allowing cells to adhere, plates
were collected at 1, 2, 3, 4, 5, 6, 7, and days. The number
of living cells was quantificationally detected by MTT
assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide), which moved the medium and then
added MTT 150 μL/well, after being incubated at 37 °C
for 4 h and put DMSO 20 μL/well for 15 min later, was
measured by micro-plate reader (Bio Med) at a wave-
length of 490 nm with background subtraction at
570 nm. Experimental conditions were executed in trip-
licate and experiments repeated three times.
Clonogenic assay
An equal number of cells were plated into 6-well plates
at a concentration of 8.0 × 102 cells/well. After 10 to
14 days of incubation, cells were fixed and stained with
crystal violet, colonies consisting of at least 50 cells were
enumerated for each group.
Multilineage differentiation studies
Cells were plated at a density of 5.0 × 104 cells/well in
24-well plates. For osteogenic differentiation, cells were
incubated in the presence of 10 mM β-glycerol phos-
phate and 100 μg/mL ascorbic acid for the indicated
times; the induction medium was changed every 3 to
4 days. Osteogenic differentiation was assessed after
21 days of incubation. Cells were fixed with 4%
formaldehyde and stained with 2% Alizarin red S
(Sigma) to visualize the formation of calcium deposits.
To induce adipogenic differentiation, cells were incu-
bated in the presence of 100 nM dexamethasone,
250 μM iso-butyl-methyl-xanthine (IBMX), 100 μM
indomethacin and 10 μg/mL insulin. To visualize adipo-
genic differentiation, cultures were fixed in 4% formalde-
hyde and stained with Oil Red O (Sigma; 3 mg in 60%
isopropanol) after 14 days in adipogenic induction
medium. Images were taken using an inverted fluores-
cence microscope (Nikon, Eclipse TS 100).
Xenograft model
Sorted cells were collected and resuspended at 1.0 × 104
cells per 50 μL PBS, 50 μL of Matrigel (BD Biosciences)
was added to each aliquot, and the cell-Matrigel suspen-
sions were subcutaneously injected into the dorsum of
3- to 4-week-old non-obese diabetic/severe combined
immunodeficiency (NOD/SCID) nude mice while under
anesthesia.
Quantitative real-time-PCR (qPCR) assay
Cellular RNA from different cell lines was collected using
the RNeasy mini Kit (Tiangen). Primers and Taqman probe
for detecting TREX1 mRNA were designed by Beacon
Designer (V.3.0, Premier BioSoft) and the sequences are in
Table 1. Real-time PCR reaction products were added in
appropriate primer pairs and then quantified by incorpo-
rated with SYBR Green I (Promega).
Western blot analysis
Total cellular proteins were harvested from incubated
cells in lysis buffer. The concentrations of proteins
were detected by BCA Protein Assay Reagent Kit
(Sangon). Western blot analysis was performed by
SDS-PAGE which was done in 10% glycine gels (Bio-
rad) by loading 50 μg of total proteins per lane. After
electrophoresis, fractioned proteins were transferred
to a nitrocellulse membrane and blocked with 5%
BSA (Bovine Serum Albumin) in TBST buffer for 1 h.
And then, the memberane was incubated with a
rabbit polyclonal primary antibody anti-TREX1 and
anti-β-actin (USA; dilution 1:1000) in blocking solu-
tion overnight at 4 °C. And then a goat anti-rabbit
IgG monoclonal antibody (dilution 1:2000) conjugated
with primary antibody at room temperature with
gentle shaking for 1 h. Protein bands were added
enhanced chemiluminescent (ECL) kit and detected
immunoreactivity by exposure to autorads.
Statistical analyses
All of the data was statistically analyzed through SPSS
17.0 software. The measurement data between the two
groups were compared using t test. The count data
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between the two groups were compared using χ2 test
and Kaplan–Meier survival analysis. P < 0.05 indicated
that the difference was statistically significant.
Results
Three-year follow-up results
The patients were divided into the metastasis group
(n = 25) and non-metastasis group (n = 20) according
to the distant metastasis to lungs, spine and retroper-
itoneum within 3 years. Among them, seven patients
were observed with metastasis at time of preliminary
diagnosis, accounting for 15.6% (7/45) of the total pa-
tients. The metastasis time spanning in the metastasis
group was from preliminary diagnosis to postoperative
20 months, averagely about 6.8 months. Average death
time was 24.4 months for the metastasis group, but three
patients exceeded 36 months accounting for 12% (3/25).
Only one patient had the longest survival time of
67 months, accounting for 4% (1/25). On the other hand,
the average survival time in the non-metastasis group was
52.6 months at the end of the 3-year follow-up visit.
HE staining of osteosarcoma tissue in two groups
In the non-metastasis group, the low power lens showed
the naive osteosarcoma tumor cells were diffusely dis-
tributed and the marrow cavity was infiltrated. More-
over, the lace-like immature osteoid tissue was observed.
The high-power lens showed that the tumor cells were
pleomorphic, polygonal, round, and irregular with the
clear boundary. The cytoplasm was abundant, slightly
basophilic and transparent. The cell nuclei were unequal-
sized. The dicaryon was observed in some cells. The shape
was irregular. The chromatin was coarse granular. 1~4
small nucleolus were observed. The nuclear fission was
observed. The mesenchyma was mucoid. A small amount
of osteoid tissue was scattered in the mesenchyma (Fig. 1a,
b). The heterogenic tumor cells were observed in the
osteosarcoma tissue in the metastasis group under low
power lens. A large number of immature osteoid tissues
were observed in the surrounding. They were parallel and
irregular. No lining osteoprogenitor or small vessel was
observed. Small amount of atypical cells were scattered
surrounding the immature osteoid tissue under high
power. The cells were irregular in shape. The nucleoplasm
Table 1 Primer pairs used in qPCR
Gene Forward primer 5′-3′ Reverse primer 5′-3′ Length
TREX1 5′-CCACTCCTTTCCTTACCACATC-3′ 5′-CCACTCCGCCAAACAGAT-3′ 106 bp
Nanog 5′-ACCTATGCCTGTGATTTGTGGG-3′ 5′-AGAAGTGGGTTGTTTGCCTTTG-3′ 169 bp
Oct4 5′-CTGAGGTGCCTGCCCTTCTA-3′ 5′-CCAACCAGTTGCCCCAAAC-3′ 166 bp
Bglap 5′-CTCACACTCCTCGCCCTATT-3′ 5′-CGCCTGGGTCTCTTCACTAC-3′ 143 bp
adipoQ 5′-CCCATTCGCTTTACCAAGAT-3′ 5′-GGCTGACCTTCACATCCTTC-3′ 139 bp
GADPH 5′-ATGACATCAAGAAGGTGGTG-3′ 5′-CATACCAGGAAATGAGCTTG-3′ 177 bp
Fig. 1 The HE staining of osteosarcoma tissue of the non-metastasis group (a, b) and metastasis group (c, d) with 100× (a, c) or 200× (b, d)
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ratio was relatively large. The chromatin was fine and
smooth. No clear nucleolus was observed. The mitotic
phenomenon was rare (Fig. 1c, d).
Expression of TREX1 protein in osteosarcoma tissues in
two groups
TREX1 protein was expressed in the cytoplasm and nu-
cleus in the osteosarcoma tissues of the non-metastasis
group. It was brown yellow to dark yellow granular,
diffusely and scatteredly distributed (Fig. 2a, b). The TREX1
protein observed in cytoplasm was faint yellow granular in
the osteosarcoma tissue of the metastasis group, scatteredly
distributed. TREX1 protein was not expressed in the
nucleus (Fig. 2c, d). The analysis by IPP6.0 software showed
that the positive rate of the non-metastasis group was high,
the positive intensity was strong and the difference was
statistically significant (P < 0.05), suggesting that TREX1
protein was highly expressed in the osteosarcoma in the
non-metastasis group.
Relationship between TREX1 expression and
clinicopathological factors in patients with osteosarcoma
There are many clinicopathologic characteristics for the
tumor tissue. All of 45 samples were divided into the
high expression group (n = 21) and low expression
group (n = 24) according to the expression of TREX1;
the P value was statistically analyzed, in order to de-
termine the correlation between the patients’ age, gender,
site, histological type, pathological stage, distant metasta-
sis, other clinicopathological factors and the expression of
TREX1. Table 2 shows that the expression of TREX1 is
not significantly correlated with the patients’ age, gender,
site, histological type or other clinicopathological factors
(P > 0.05); the higher the pathological stage possessed the
lower the expression of TREX1, suggesting that the TREX1
was significantly correlated with the Enneking stage of
osteosarcoma and the expression of TREX1 protein in the
metastasis group was significantly lower than that of non-
metastasis group (P < 0.05).
Kaplan–Meier survival analysis of TREX1 and prognosis of
patients with osteosarcoma
The single factor analysis of 45 patients with osteosar-
coma showed that the expression of TREX1 was an inde-
pendent factor affecting the patients’ prognosis (P <
0.05). The expression of TREX1 was positively related to
the prognosis of patients with osteosarcoma, namely the
higher the expression of TREX1 was, the longer the pa-
tients’ survival time (Fig. 3).
Sorting of human osteosarcoma stem cells
The proportions of fluorescent P2 cells subset (CD133+
cell subset) in MNNG/HOS, MG-63 and U-2 OS cell
lines fluctuated in 1~5%, averagely about 3%. The difference
was not statistically significant between the cell lines (P >
0.05), as shown in (Fig. 4). This suggested that the propor-
tions of CD133+ cell subsets were roughly equal in human
osteosarcoma cell lines, namely that the proportion of
osteosarcoma stem cells was constant. Any cell line can be
selected to study the biological characteristics of osteosar-
coma stem cell as a research carrier. Considering that the
stem cells sorted by osteosarcoma MNNG/HOS cell
Fig. 2 The expressions of TREX1 protein of osteosarcoma tissue of the non-metastasis group (a, b) and metastasis group (c, d) with 100× (a, c) or
200× (b, d)
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formed the tumor earlier and the tumor was larger, thus,
osteosarcoma cells line MNNG/HOS CD133+ cell subset
was selected as the research object.
Tumorsphere culture after isolation of human
osteosarcoma stem cells
The tumorsphere was cultured in the serum-free stem
cell medium. CD133+ cells aggregated into clusters
after incubation for 24 h. The tumorspheres were
gradually increased. The tumorsphere was not in-
creased significantly 7 days later (Fig. 5a). While,
CD133− cells were in single state in after 24 h incuba-
tion. There was no significant tumorsphere after
culture for 7 days (Fig. 5b). Only scattered cells aggre-
gating into small clusters were found, which was just
equivalent to the tumor volume of the culture of
CD133+ cells subset for 24 h. The difference was
statistically significant (P < 0.05). The results showed
that the CD133+ cell subset had obvious stem cell
characteristics, had higher rate and larger volume of
tumor-forming and the proliferation was rapid.
Biological characteristics of human osteosarcoma MNNG/
HOS stem cell subsets
MTTassay showed that CD133+ cell subsets entered loga-
rithmic phase after inoculation for 3~7 days. The OD
values of CD133+ cell subsets were higher than that of
CD133− cell subset and the difference was statistically
significant (P < 0.05), as shown in (Fig. 6), suggesting that
the growth and proliferation abilities of CD133+ cell
subsets in osteosarcoma MNNG/HOS cells were stronger.
CD133+ cell subset sorted from human osteosarcoma
MNNG/HOS cells had a strong ability of clone formation.
The sorted cells were inoculated, respectively, in two
groups, which were repeated for three times (Fig. 7a). The
number of colonies was calculated after culture for
2 weeks. The mean number of total clone was counted.
The clone number of CD133+ cell subsets was (24 ± 3.16),
which was significantly higher than that of the CD133−
cell subset (12 + 2.41). And, the difference was statistically
significant between the two groups (P < 0.05) (Fig. 7b).
After CD133+ cell subsets in human osteosarcoma
MNNG/HOS cells were inoculated subcutaneously in
nude mice, the tumor easily formed. After 1.0 × 104 cells
were inoculated for 12 days, small nodules formed. And,
the tumor increased and formed obviously in 4 weeks
(Fig. 8a). While no obvious tumor growth was observed in
CD133− cell subset inoculation area in the control group
with the same cells inoculated in 4 weeks (Fig. 8b).
Osteogenic and adipogenic induction
After the osteogenic induction of CD133+ cell subsets in
human osteosarcoma MNNG/HOS cells for 18 days, a
lot of calcium nodules were investigated through Alcian
Table 2 Expression of TREX1 protein in human osteosarcoma
tissue and its relation with the clinical biological behavior of
osteosarcoma




























aOthers (telangiectatic, small cell, parosteal, undifferentiated osteosarcoma)
Fig. 3 Kaplan–Meier curves displaying the survival of patients with
different expression levels of TREX1 protein
Feng et al. Journal of Orthopaedic Surgery and Research  (2016) 11:150 Page 6 of 13
Fig. 4 Sorting of human osteosarcoma cells. Left the cell subsets with the detection of CD133+ (P2). Right were the isotype controls
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staining (Fig. 9a), while only individual calcium nodules
can be found in CD133- cell subsets (Fig. 9b). Similarly,
after the adipogenic induction of the former for 21 days, a
large number of small lipid droplets were found through
oil red staining (Fig. 9c), while the lipid droplet was not
found in the latter (Fig. 9d). The expressions of osteogen-
esis gene Bglap and adipogenic gene adipoQ in CD133+
and CD133− cell subsets were detected, respectively, by
qPCR. The results showed that the mRNA expressions of
Bglap and adipoQ were more significantly increased in
CD133+ cell subset, about 3~4 times than that in CD133-
cell subset, and the difference was statistically significant
(P < 0.05) (Fig. 9e, f ), suggesting that the CD133+ cell sub-
set had the significant differentiation potential of the char-
acteristics of osteosarcoma of osteogenic and adipogenic.
Chemotherapy sensitivity test
The human osteosarcoma MNNG/HOS cells were inoc-
ulated in 96-well plates and cultured. The OD values
were measured at different time-points after cisplatin
was added according to the concentration gradient. The
OD values divided by the OD values in the negative con-
trol group were used as the survival rate (SR). The low
concentration (0.5 μmol/L) of cisplatinum had almost
no inhibiting effect on osteosarcoma cells in two groups.
With the increase of cisplatinum concentration and the
extension of drug action, the survival ratios in two subsets
were decreased gradually, but the decrease of CD133− cell
subset was more significant. The difference was statisti-
cally significant (P < 0.05) when the concentration was
≤5 μmol/L for 72 h (Fig. 10a, b). When 10 μmol/L cisplati-
num was used for 48 h, the difference was statistically
significant (P < 0.05), while the difference was not statisti-
cally significant (P > 0.05) when the concentration of
cisplatinum was 10 μmol for continuous 72 h (Fig. 10c).
Expressions of osteosarcoma stem cells related genes
Nanog and Oct4
The expressions of stem cell-related genes Nanog and
Oct4 in osteosarcoma MNNG/HOS were detected by
qPCR. The expressions of Nanog and Oct4 of CD133+
cell subset were higher than those of CD133− cell subset,
and the difference was statistically significant (P < 0.05),
as shown in (Fig. 11).
Fig. 5 The contrast of the formation abilities of tumorsphere of CD133+ cell subsets (a) and CD133− cell subsets (b) (100×)
Fig. 6 The proliferation of CD133+ and CD133− cell subsets in
human osteosarcoma MNNG/HOS cells (MTT assay)
Fig. 7 The contrast of the clone forming ability (a: sorted cells; b:
the statistical analysis) of CD133+ and CD133− cell subsets in human
osteosarcoma MNNG/HOS cells
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Expression of TREX1 in human osteosarcoma MNNG/HOS
cell subsets
The expression of TREX1 mRNA in the sorted
CD133− cell subsets was 5~6 times of CD133+ cell
subset by qPCR, and the difference was statistically
significant (P < 0.05), as shown in (Fig. 12a). The pro-
tein was isolated and tested by Western blot. The
grey level was calculated using the ImageJ software.
The CD133−/CD133+ ratio was 2.5, namely the
expression of TREX1 protein in the sorted CD133−
Fig. 8 The tumor growth of the inoculation of human osteosarcoma CD133+ (a) and CD133− (b) cell subsets in nude mice
Fig. 9 The osteogenic induction (a, b), adipogenic induction (c, d), and expressions of osteogenesis gene Bglap (e) and adipogenic gene adipoQ
(f) of CD133+ (a, c) and CD133− (b, d) cell subsets in human osteosarcoma MNNG/HOS cells
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cell subsets was 2.5 times of CD133+ cell subsets, and
the difference was statistically significant (P < 0.05), as
shown in (Fig. 12b), suggesting that the expression of
TREX1 in CD133+ cell subset with the nature of
osteosarcoma stem cells was significantly lower than
that of CD133− cell subsets in non-osteosarcoma stem
cells.
Discussion
Osteosarcoma is the most common primary malignant
bone tumor in children and adolescents [1]. Although
neoadjuvant chemotherapy combined with surgical re-
section can improve the 5-year survival rate, the overall
prognosis is unsatisfactory. Distant metastasis is the
main cause of death in patients with osteosarcoma. Pre-
vious studies report that 20% of patients have distant
metastatic lesions at the initial diagnosis. In contrast,
80% of patients develop metastasis after the surgery [15].
In this group, 15.6% (7/45) of the patients occurred
metastasis in the preliminary diagnosis, which was simi-
lar with that of the literature [15]. More than half of the
patients occurred to metastasis within 3 years after the
operation (25/45). The follow-up visit found that the
survival time in the metastasis group was significantly
lower than that of non-metastasis group. The average
time to metastasis was 6.8 months and with the average
survival time of 24.4 months in the metastatic group.
While the average survival time for the non-metastatic
group was 52.6 months. The average survival time of the
metastasis group with the discovery of metastasis was
only 18 months. The result of follow-up visit showed
that the metastasis time was different from the prelimin-
ary diagnosis to the postoperative 20 months in the
metastasis group. Combined with the results that the
metastasis time was about 18 months from the discovery
of metastasis to death, the survival time of most patients
was less than 3 years, and the number of patients whose
survival time was more than 3 years in the metastasis
Fig. 10 Effect of different concentrations of cisplatin on the survival rate of CD133+ and CD133− cell subsets in human osteosarcoma MNNG/HOS
cells in different time (a:24 h; b:48 h and c:72 h)
Fig. 11 The expressions of stem cell-related genes Nanog and Oct4 in CD133+ and CD133− cell subsets of human osteosarcoma MNNG/HOS cell
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group was only 12% (3/25) up to the end of the follow-
up visit, the time boundary was established as 3 years in
this work to facilitate the control study.
To improve the 5-year survival rate of patients with
osteosarcoma, the metastasis of osteosarcoma must be
effectively prevented. A large number of clinical trial
proved that the metastatic tumors had multi-drug resist-
ance to chemotherapy drugs. Lung metastatic tumor was
inconsistent with the biological characteristics of pri-
mary tumor [2–5], resulting that the chemotherapy
drugs being sensitive to the pathological type of primary
osteosarcoma was insensitive even resistant to the meta-
static tumor. Recent studies suggest that tumor stem
cells may be the cause of drug resistance and metastasis
of malignant tumors. Further study on the biological
characteristics of tumor stem cells may help us to clarify
the drug resistance mechanism of tumor, to develop the
specific targeted drug and to improve the survival of
patients with malignant tumor.
TREX1 gene correlation with tumors has attracted the
attention of scholars in recent years [16–19]. Dong et al.
[20] analyzed the genotype and survival rate of over 700
patients with pancreatic cancer. The result found that
TREX1 gene could be applied as one of the important
predictive factors for the overall survival rate of patients
with pancreatic cancer. However, no study on TREX1
gene was reported on other solid tumors [18]. It is
unclear if it is suitable as a predictive factor for other
tumors. Immunohistochemistry experiment showed that
the morphologies of tumor cells were irregular in 25
cases of patients with osteosarcoma. The nucleoplasm
ratio was relatively large. The chromatin was fine and
smooth. The nucleoli were not obvious. The nuclear
fission was rare. TREX1 protein was lowly expressed in
21 cases of patients in the metastasis group, suggesting
that the expression of TREX1 was closely related to the
lung metastasis in osteosarcoma. Further analysis
showed that the expression of TREX1 was high in pa-
tients at stage I and most patients at stage II, while the
expression of TREX1 was low in patients at stage IIb
and stage III, the expression of TREX1 was related to
the patients’ Enneking stage (P < 0.05). There was no
significant correlation between the expression of TREX1
and the type of osteosarcoma. The higher the expression
of TREX1 was the longer the survival time. Therefore,
the expression of TREX1 can be used as an effective
index to jugde the prognosis of patients with osteosar-
coma. However, the number of cases in this group is
relatively few. More cases should be analyzed and
followed-up longer in order to confirm the significance
of this prognostic indicator. The cytology experiment in
vitro on the correlation between the expression of
TREX1 and the biological characteristics of osteosar-
coma stem cells was further studied.
The tumor stem cells can be isolated from a variety of
tumor cells by different methods [21, 22]. At present,
CD133, CD117, and Stro-1 are mostly used in osteosar-
coma stem cell surface marker sorting. Among them,
the combined sorting of CD117 and Stro-1 should be
performed. Moreover, CD133 can be used as a cell
marker to sort osteosarcoma cell lines MG-63, U-2OS
and Saos-2 [23, 24]. In the experiment, the human
CD133 antibody was used as the osteosarcoma stem cell
surface markers by flow sorting. Three strains human
MNNG/HOS, MG-63 and U-2 OS cells were sorted.
The proportion of osteosarcoma stem cells fluctuate be-
tween 1 and 5%, with an average of 3%. The proportions
of osteosarcoma stem cells were constant in different
cell lines, which is comparable in the literature [23]. Any
cell line can be used as the carrier for the next step ex-
periment. Combined with the report in the literature,
the osteosarcoma stem cell sorted from MNNG/HOS
cells could enable the tumor form in non-obese diabetic
(NOD) or severe combined immunodeficiency (SCID)
and the tumor volume was larger [25]. Thus, the human
osteosarcoma MNNG/HOS cell line was selected in the
experiment.
Tumorsphere culture is the gold standard in the isola-
tion and identification of stem cells. It is widely used in
the identification of cancer stem cells after isoltion [23].
The CD133+ cell subsets were sorted out after CD133
antibody labeling. Then the tumorsphere culture experi-
ment was performed, so as to further verify whether the
CD133+ cell subsets were osteosarcoma stem cells. The
Fig. 12 The expressions of TREX1 mRNA (a) and protein (b) in CD133+ and CD133− cell subsets of human osteosarcoma MNNG/HOS cell
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tumorsphere culture found that the tumorsphere formed
in the sorted CD133+ cell subsets with osteosarcoma
stem cell characteristics after culture for 7 days. While
no tumorsphere formed in the control group (CD133−
cells), this only confirms that the sorted CD133+ cells
were the osteosarcoma stem cells. The tumor stem cells
can form tumorspheres. The growth of CD133+ cell subsets
was verified through growth curve assay (MTT), clone
formation, osteogenic and adipogenic differentiation, nude
mice tumor-forming capacity, and chemotherapy drug sen-
sitivity test. Compared with CD133− cell subsets in the con-
trol group, the OD values of CD133+ cell subsets were
higher at different time-points in the logarithmic growth
phase; after the same number of cells was added in the
colony forming experiment, the colony-forming units were
more and the colony area was larger; after osteogenic and
adipogenic induction, the osteogenic and adipogenic differ-
entiation was observed. The osteogenic and adipogenic
genes Bglap and adipoQ were highly expressed. After 1.0 ×
104 cells were inoculated in nude mice, tumor formed.
Twelve days later, 1.0 × 104 CD133− cells were then inocu-
lated in the control group and extended to 4 weeks. No
tumor growth was seen. After adding cisplatin, the survival
rate was higher in equally distributed drug concentrations.
The biological characteristics verified that the sorted
CD133+ cell subsets were osteosarcoma stem cells. There
were more colony-forming units. The potential of osteo-
genic and adipogenic differentiation was strong. The
tumor-forming capacity in vivo was strong. The cells were
resistant to the chemotherapy drugs. These were consistent
with the characteristics of the sorted osteosarcoma stem
cells in the literatures [23, 25]. CD133− cells had no osteo-
sarcoma stem cell-related characteristics, that was failure to
form tumorspheres, weak ability of cell proliferation, less
colony-forming units, no obvious differentiation potential
or tumor-forming capacity in nude mice, and high sensitiv-
ity to chemotherapy drug cisplatin. In addition, the stem
cell-related genes Nanog and Oct4 were highly expressed in
CD133+ cells by qPCR, which was about 2~4 times of
CD133- cells. The expressions of TREX1 mRNA and pro-
tein in CD133− cells of human osteosarcoma MNNG/HOS
cells were significantly higher than those of CD133+ cells,
suggesting that TREX1 was lowly expressed in osteosar-
coma stem cells and highly expressed in non-osteosarcoma
stem cells, indicating that the expressions of TREX1 gene
and protein were closely related to osteosarcoma cell stem
cell properties, also indicated that the expression of TREX1
could indicate the stem cell characteristics of osteosarcoma
cells, illustrating the proliferation and metastasis of osteo-
sarcoma cells.
Patients in the metastatic group showed a low or no
expression of TREX1, while the non-metastatic group
expressed high TREX1 protein. Chemotherapy drug resist-
ance is considered as the main reason for the poor
prognosis in the metastatic group. Low expression of
TREX1 and resistance to cisplatin in CD133+ cells were
observed indicating TREX1 gene was related to the drug
resistance of osteosarcoma, which was consistent with the
previous report [26]. Thus, the expression of TREX1 was
closely related to the drug resistance, relapse and metasta-
sis of osteosarcoma stem cells, and the expression of
TREX1 could indicate the prognosis of osteosarcoma.
Conclusions
The expression of TREX1 may be related to metastasis
in patients with osteosarcoma. The expression of TREX1
was closely related to the cytobiology characteristics of
osteosarcoma stem cell. TREX1 can play an important
role in the occurrence and development processes. And
TREX1 is expected to become an effective new index for
the evaluation of the prognosis. This was the preliminary
experimental result based on the current clinical case,
and a larger osteosarcoma sample validation was needed
to confirm this result.
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